Lead extraction in chronic kidney disease: navigating risk and recovery

The number of Australians living with a permanent pacemaker or implantable cardioverter-defibrillator continues to climb, driven by an ageing population and expanding indications for cardiac resynchronisation therapy. Within that group, a sizeable subset also carries a diagnosis of chronic kidney disease, where uremic milieu, vascular calcification, and impaired immunity converge to amplify the hazards of long-term device therapy. When infection, lead failure, or venous occlusion ultimately forces a referral for transvenous lead extraction, the clinical calculus becomes considerably more delicate than in patients with preserved renal function.

This synthesis examines the contemporary evidence on risk factors and outcomes among patients with chronic kidney disease undergoing lead extraction, with attention to those on maintenance dialysis. It also considers Australian registry data, regional practice patterns, and peri-procedural strategies that can shift the balance towards safer extraction in this vulnerable cohort.

Vascular access, calcification, and lead adhesions

Patients with advanced renal impairment develop a distinct lead-tissue interface. Calcium phosphate deposition along the subclavian and brachiocephalic vessels stiffens the venous wall and tethers the lead body in fibrotic, often mineralised, scar tissue. Intravascular ultrasound and contrast-enhanced CT performed at Australian tertiary centres such as Royal Melbourne Hospital and Westmead frequently demonstrate superior vena cava narrowing and dense lead-to-wall adherence that preclude simple manual traction. These anatomical changes lengthen case duration, raise fluoroscopy dose, and increase reliance on powered sheaths.

The chronic inflammatory state of uraemia amplifies fibrotic encapsulation around the lead tip, particularly in the right ventricle. Operators planning extraction in patients with an estimated glomerular filtration rate below 30 mL/min/1.73 m² should anticipate that counter-traction techniques will be required in a higher proportion of cases. Pre-procedural imaging that maps lead trajectory, identifies extravascular extensions of the helix, and quantifies intravascular calcification has become a routine component of the work-up at high-volume Australian sites, helping the procedural team to select the appropriate extraction toolset and inform consent.

Risk stratification and predictive scoring

Several tools have been proposed to forecast major adverse events during transvenous lead extraction, including the SAFeTY, ELECTRa, and MB score systems. In renal cohorts, the most consistently informative variables are long lead dwell time, multiple leads, previous extraction attempts, and the severity of kidney dysfunction itself. Serum creatinine, dialysis vintage, and the presence of anaemia requiring transfusion support all behave as independent predictors in multivariate analyses.

Practical scoring in the Australian context often adds a layer of logistical risk. Patients travelling from regional Queensland, Western Australia, or the Northern Territory for a quaternary extraction service face prolonged inter-hospital transfer times, and tertiary referral hubs in Sydney, Melbourne, and Adelaide have begun embedding telehealth preoperative review into their pathways. Documenting access to a cardiothoracic surgical backup, on-site perfusion, and blood bank capability is now as much a part of the risk assessment as the lead characteristics themselves, particularly when the local centre is hundreds of kilometres from the nearest rescue facility.

Haemorrhagic and infectious complications

Bleeding remains the most feared procedural complication in this group. Uraemic platelet dysfunction, concurrent antiplatelet therapy for coronary disease, and anticoagulation for atrial fibrillation create a triple-layered haemostatic challenge. Tamponade from superior vena cava or right atrial tears can escalate rapidly, and a substantial proportion of renal patients require pericardiocentesis, emergency sternotomy, or endovascular balloon occlusion to control the source. Operators therefore default to lower activated clotting time targets, pre-procedure desmopressin in selected cases, and meticulous sheath exchanges.

Device infection adds its own dimension. Pocket erosion, generator site cellulitis, and lead-dependent endocarditis occur at markedly higher rates among dialysis patients, with Staphylococcus aureus bacteraemia being particularly prevalent. Long courses of targeted intravenous antibiotics are required before any extraction attempt, and a coordinated antimicrobial stewardship plan across the cardiology, nephrology, and infectious diseases teams is essential. Recovery on outpatient parenteral antibiotic therapy is well established in metropolitan Australia but becomes logistically complex once the patient returns to a satellite dialysis unit in a regional town, where vascular access nursing and pharmacy support may be limited.

Dialysis-dependent versus non-dialysis cohorts

Comparative registry work consistently shows that in-hospital mortality, major bleeding, and one-year all-cause mortality are each elevated in patients on maintenance haemodialysis compared with non-dialysis CKD counterparts. Procedure-related mortality in some series approaches three to four per cent in the dialysis group, several times the rate seen in patients with an estimated glomerular filtration rate above 60 mL/min/1.73 m². Septic complications, persistent bacteraemia, and progressive heart failure account for much of the excess late mortality.

Counterbalancing these sobering numbers are the consequences of withholding extraction. Retained infected hardware in a dialysis patient carries mortality that often exceeds that of the procedure itself. Clinicians in Australian practice therefore approach the decision as one of relative risk, engaging patients and families in nuanced discussions about the alternative pathways of suppressive antibiotics, lead abandonment with contralateral re-implantation, or careful extraction with intensive peri-procedural support. The cardiac memory phenomenon occasionally confounds post-procedural rhythm assessment, particularly in patients with chronically paced ventricles whose native conduction has been suppressed.

Australian registries and centre experience

Data from the Australian and New Zealand Society of Cardiac and Thoracic Surgeons, alongside single-centre series from major metropolitan hospitals, have begun to characterise local outcomes. Extraction volumes remain modest compared with European registries, with the highest case throughput reported at the Royal Adelaide, Royal Prince Alfred, and MonashHeart services. Case-mix differs slightly from overseas reports, with a relatively higher proportion of remote and rural patients referred late in the disease course and a notable representation of Aboriginal and Torres Strait Islander Australians, in whom chronic kidney disease prevalence is substantially elevated.

The Therapeutic Goods Administration regulates the powered sheath devices and laser-assisted tools available in Australian practice, and recent regulatory updates have shaped which technologies local centres can deploy. Hospital funding through the Medicare Benefits Schedule and activity-based casemix models influences both the choice of anaesthetic support and the duration of postoperative monitoring, which has prompted some services to standardise overnight recovery in a coronary care or high-dependency setting rather than a general cardiology ward for higher-risk renal extractions.

Peri-procedural optimisation and multidisciplinary care

Pre-operative optimisation is where outcomes are often decided. Volume status is corrected with the patient's routine dialysis schedule, potassium and acid-base balance are checked within hours of the procedure, and any pulmonary hypertension contributing to right heart strain is characterised echocardiographically. Anaemia is corrected to a target that balances transfusion risk against procedural oxygen delivery, and nephrology input ensures that contrast exposure is minimised during pre-procedural imaging.

Intra-procedurally, transoesophageal echocardiography, invasive arterial monitoring, and immediate availability of cardiothoracic surgery form the safety net. Post-procedural care includes careful reinitiation of anticoagulation, renal-dose adjustment of antibiotics and analgesics, and clear handover back to the dialysis unit regarding vascular access preservation. Where re-implantation is required, contralateral placement, subcutaneous defibrillator use in selected cases, or leadless pacing options are considered. A structured outpatient follow-up at four to six weeks allows wound review, pacing checks, and reassessment of renal trajectory.

Practitioners seeking a broader overview of how cardiac arrhythmia burden influences prognosis in comorbid populations can find additional context in a recent feature on pulmonary hypertension arrhythmia prognosis, which highlights shared mechanisms of right ventricular strain and arrhythmia-mediated mortality that resonate with the renal cohort.

Clinicians managing these complex patients across Australia are encouraged to contribute to and consult the journal's growing evidence base. Submission details and editorial scope are outlined on the journal's About page. Submitting case series, registry analyses, or educational reviews to the Journal of Arrhythmia helps refine the multidisciplinary pathways that make lead extraction safer for renal patients, and strengthens the Asia-Pacific voice in this rapidly evolving field.